Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.51

-1.3%

Jan 16 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (10840)	3/4/2004 8:28:05 PM
From: Sidney Street	Read Replies (1) of 52153

One person I spoke with about the MS clinical situation characterized it as a chronic situation where patients work their way through the medications including Avonex and Rebif, using them each for a period, but they are left facing deteriorating health and a need for another treatment. Apparently there are patients doubling and tripling their Rebif doses, but the person I spoke to said those patients would be needing a new therapy because increased beta-interferon dosage is a short term strategy, and they are, in effect, being "primed" for Antegren. I plead ignorance of the MS treatment picture, and I'm long ELN by way of disclosure. I pass this along as much for the general point that it's useful to consider the likely behavior of clinicians as for the anecdotal evidence re: the MS therapy picture.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next